[Ip-health] HAI/Oxfam/MSF: Solutions to improve access to medicines and biomedical innovation through EU trade and R&D policy

Tessel Mellema tessel at haieurope.org
Mon Nov 24 01:14:11 PST 2014

Citizens in developing countries have long suffered from a lack of access to affordable and effective medicines. As a result of the global financial crisis, a growing number of EU citizens are now experiencing similar problems. Better government policy could turn this around. The EU's current trade and R&D policies promote excessive intellectual property protection-an approach that drives up medicine costs and drives down needs-driven biomedical innovation.

HAI Europe, Médecins Sans Frontières - Access Campaign and Oxfam are offering policy-makers seven straight-forward solutions that could transform harmful trade and R&D policy. By taking these solutions on board, the EU could enhance medicines access and pharmaceutical innovation in the EU and around the world.

The solutions are available here: http://haieurope.org/wp-content/uploads/2014/11/Solutions-to-improve-A2M-and-biomedical-innovation.pdf.

For further information, please contact HAI Europe policy advisors, Tessel Mellema (tessel at haieurope.org<mailto:tessel at haieurope.org>) and Aliénor Devaliére (alienor at haieurope.org<mailto:alienor at haieurope.org>).

Tessel Mellema
Policy Advisor

Health Action International (HAI) Europe
Overtoom 60 (2)
1054 HK Amsterdam
The Netherlands
T: +31 (0) 20 683 3684
M: +31 (0) 6 24686771
E: tessel at haieurope.org

Health Action International (HAI) Europe is an independent network working to increase access to essential medicines and improve their rational use through research excellence and evidence-based advocacy.

More information about the Ip-health mailing list